Novartis AG

Riding high on the wave of its dual GIP/GLP-1 agonist, tirzepatide, Eli Lilly awarded its CEO the highest total remuneration package of the top 12 big pharma companies in 2024. David Ricks’s total com

SpliceBio already had the backing from the venture arms of two pharma companies – UCB and Novartis – and two other big players in the industry have participated in an impressive second funding round f

Merck & Co. could have an edge in the cholesterol market with the first oral PCSK9 inhibitor. The company announced positive topline data on June 9 from the first two Phase III trials testing enli

For the third time, the US Federal Trade Commission has sent warning letters to drug companies, disputing improperly listed patents in the US Food and Drug Administration’s Orange Book. The agency tar